CervoMed Inc.
A clinical-stage biotech developing treatments for age-related neurologic disorders.
CRVO | US
Overview
Corporate Details
- ISIN(s):
- US2537484048 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 20 PARK PLAZA, 2116 BOSTON
- Website:
- https://cervomed.com/
Description
CervoMed Inc. is a clinical-stage biotechnology company that develops treatments for age-related neurologic disorders. The company focuses on neurodegenerative diseases, including Dementia with Lewy Bodies (DLB), Alzheimer's, and Huntington's disease. Its lead investigational candidate is neflamapimod, an orally administered, small molecule brain penetrant that inhibits the p38 alpha protein kinase. CervoMed's scientific approach is based on early intervention to reverse synaptic dysfunction, which is considered a reversible aspect of the neurodegenerative process, before the onset of irreversible nerve cell death. The company is advancing neflamapimod through clinical trials, including a Phase 2 study for patients with DLB.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-04 13:08 |
8-K - CervoMed Inc. (0001053691) (Filer)
|
English | 80.6 KB |
Automate Your Workflow. Get a real-time feed of all CervoMed Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CervoMed Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CervoMed Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
